CHILDHOOD MASTOCYTOSIS NEW DEVELOPMENTS IN DIAGNOSIS AND TREATMENT

CHI775LDHOOD_MASTOCYTOSI775S_NEW_DEVELOPMENTS_IN_DI775AGNOSI775S_AND_TREATMENTKAPAK

CHILDHOOD MASTOCYTOSIS AND QUALITY OF LIFE: PSYCHOSOCIAL IMPACTS AND SUPPORT

Figen Çelebi Çelik

İzmir Dr. Behçet Uz Child Disease and Pediatric Surgery Training and Research Hospital, Department of Pediatric Immunology and Allergy, İzmir, Türkiye

Çelebi Çelik F. Childhood Mastocytosis and Quality of Life: Psychosocial Impacts and Support. In: Özdemir Ö, editor. Childhood Mastocytosis: New Developments in Diagnosis and Treatment. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.235-243.

ABSTRACT

Childhood mastocytosis often presents as cutaneous mastocytosis (CM), a benign and self-limiting con- dition. A minority of patients develop systemic mastocytosis (SM), which persists into adulthood. It is a chronic disease with a diverse and complex clinical course, causing physical and psychological findings due to mast cell infiltration or the release of mast cell mediators. Despite advances in understanding the disease, it remains poorly recognized by both physicians and the public. Patients often lack sufficient knowledge about symptoms and triggers, and their daily lives are impacted by unpredictable symptoms and the fear of anaphylaxis. Additionally, they may experience daily physical, emotional, and social stress due to stigma and exclusion by peers. Studies have reported a decline in quality of life (QoL) due to the psychosocial effects of physical and neuropsychiatric symptoms. QoL assessments provide valuable insight into both the physical and psychosocial aspects of the disease from the patient’s per- spective. Multifaceted, national and international collaborative approaches and supports are essential to meet the needs of patients, families and caregivers and to improve health-related quality of life.

Keywords: Child; Mastocytosis; Quality of life (QoL); Psychosocial support systems

Referanslar

  1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: A con-sensus proposal. Leuk Res.2001;25:603-25. [Crossref]  [PubMed]
  2. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419-32. [Crossref]  [PubMed]
  3. Vardiman JW, Thiele J, Arber DA, Brunning RD, BorowitzMJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood.2009;114(5):937-51. [Crossref]  [PubMed]
  4. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am. 2014;34(2):207-18. [Crossref]  [PubMed]
  5. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021;5(11):e646. [Crossref]  [PubMed]  [PMC]
  6. Klaiber N, Kumar S, Irani AM. Mastocytosis in Children. Curr Allergy Asthma Reports. 2017;17:80. [Crossref]  [PubMed]
  7. Giona F. Pediatric Mastocytosis: An Update. Mediterr J Hematol Infect Dis. 2021;13(1):e2021069. [Crossref]  [PubMed]  [PMC]
  8. Polivka L, Bodemer C. Chapter 92: Paediatric Mastocytosis. In: Hoeger P, Kinsler V, Yan A, eds. Harper's Textbook of Pediatric Dermatology, 4th ed. John Wiley & Sons Ltd; 2020.p.1097-1109. [Crossref]
  9. Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, et al. Patient Perceptions in Mast Cell Disorders. Immunol Allergy Clin North Am. 2018;38(3):505-25. [Crossref]  [PubMed]
  10. The Mast Cell Disease Society ©2025. [Link]
  11. Jennings SV, Finnerty CC, Hobart JS, Martín-Martínez M, Sinclair KA, Slee VM, et al. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond. J Allergy Clin Immunol Pract. 2022;10(8):2039-51. [Crossref]  [PubMed]
  12. Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, et al. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy. 2016;71(6):869-77. [Crossref]  [PubMed]
  13. Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2(1):70-6. [Crossref]  [PubMed]
  14. Lee P, George TI, Shi H, Evans EK, Singh T, Boral AL, et al. Systemic mastocytosis patient experience from mast cell connect, the first patient-reported registry for mastocytosis. Blood. 2016;128(22):4783. [Crossref]
  15. van Anrooij B, Kluin-Nelemans JC, Safy M, Flokstra-de Blok BM, Oude Elberink JN. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71(11):1585-93. [Crossref]  [PubMed]
  16. Heinze A, Kuemmet TJ, Chiu YE, Galbraith SS. Longitudinal Study of Pediatric Urticaria Pigmentosa. Pediatr Dermatol. 2017;34(2):144-9. [Crossref]  [PubMed]
  17. Sagües-Sesé E, García-Casares N, Álvarez-Twose I. Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review. Clin Transl Allergy. 2023;13(12):e12319. [Crossref]  [PubMed]  [PMC]
  18. Seamens A, Taussig B, Penziner K, Smidt A, Lawley LP. Exploring the prevalence of learning disabilities in children with cutaneous mastocytosis: a pilot cohort study. J Am Acad Dermatol. 2016;75(6):1254-5. [Crossref]  [PubMed]
  19. Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol. 2009;22(4):859-65. [Crossref]  [PubMed]
  20. Theoharides TC. Mast cells and stress--a psychoneuroimmunological perspective. J Clin Psychopharmacol.2002;22(2):103-8. [Crossref]  [PubMed]
  21. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35-45. [Crossref]  [PubMed]
  22. Georgin-Lavialle S, Moura DS, Salvador A, Chauvet-Gelinier JC, Launay JM, Damaj G, et al. Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. Mol Psychiatry. 2016;21(11):1511-6. [Crossref]  [PubMed]
  23. Gurnee EA, Phung TL, Guo E, Fong A, Tollefson M, Nguyen H, et al. Neurocognitive dysfunction and anaphylaxis in pediatric maculopapular cutaneous mastocytosis. J Allergy Clin Immunol Pract. 2020;8(1):409-10. [Crossref]  [PubMed]
  24. Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999;2(2):113-27. [Crossref]  [PubMed]
  25. Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84:205-11. [Crossref]  [PubMed]  [PMC]
  26. Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145-51. [Crossref]  [PubMed]
  27. Vlachioti E, Matziou V, Perdikaris P, Mitsiou M, Stylianou C, Tsoumakas K, et al. Assessment of quality of life of children and adolescents with cancer during their treatment. Jpn J Clin Oncol. 2016;46(5):453-61. [Crossref]  [PubMed]
  28. Eser E, Yuksel H, Baydur H, et al. Testing psychometric properties of the Turkish version of the KINDL-R, generic HRQoL measure for children. ISOQOL. 2005; 14(9): 2004. [PubMed]
  29. Cakin Memik N, Ağaoğlu B, Coşkun A, Uneri OS, Karakaya I. Cocuklar Için Yaşam Kalitesi Olçeğinin 13-18 Yaş Ergen Formunun Geçerlik ve Güvenilirliği [The validity and reliability of the Turkish Pediatric Quality of Life Inventory for children 13-18 years old]. Turk Psikiyatri Derg.2007;18(4):353-63 [PubMed]
  30. Ozdogan H, Ruperto N, Kasapçopur O, Bakkaloglu A, Arisoy N, Ozen S, et al. The Turkish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol. 2001;19(4 Suppl 23):158-62. [PubMed]
  31. Oztürkcan S, Ermertcan AT, Eser E, Sahin MT. Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol. 2006;45(11):1300-7. [Crossref]  [PubMed]
  32. Durmaz AM, Özdemir Ö. Clinical spectrum of patients diagnosed with childhood mastocytosis: a retrospective single center experience. Eur Ann Allergy Clin Immunol. 2024 Jun 24. [Crossref]  [PubMed]
  33. Spolak-Bobryk N, Niedoszytko M, Jassem E, Chełmińska M, Lange M, Majkowicz M, et al. Assessing quality of life in patients with mastocytosis: development of the disease-specific questionnaire. Postepy Dermatol Alergol.2021;38(6):1044-51. [Crossref]  [PubMed]  [PMC]
  34. Di Agosta E, Salvati L, Corazza M, Baiardini I, Ambrogio F, Angileri, et al. Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder. Clin Mol Allergy. 2021;19(1):26. [Crossref]  [PubMed]  [PMC]
  35. Vermeiren MR, Kranenburg LW, van Daele PLA, Gerth van Wijk R, Hermans MAW. Psychological functioning and quality of life in patients with mastocytosis: A cross-sectional study. Ann Allergy Asthma Immunol. 2020;124(4):373-78.e2. [Crossref]  [PubMed]
  36. Krapić M, Kavazović I, Wensveen FM. Immunological mechanisms of sickness behavior in viral infection. Viruses. 2021;13(11):2245. [Crossref]  [PubMed]  [PMC]
  37. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147-52. [Crossref]  [PubMed]
  38. Levedahl KH, Nilsson A, Ungerstedt J, Hedström M. Living with systemic mastocytosis: Balancing between vulnerability and resilience: A qualitative study. Eur J OncolNurs.2022;60:102172. [Crossref]  [PubMed]
  39. Spolak-Bobryk N, Niedoszytko M, Jassem E, Chełmiñska M, Lange M, Majkowicz M, et al. The role of the clinical and psychological symptoms of mastocytosis in the patient's quality of life. Postepy Dermatol Alergol. 2022;39(4):688-96. [Crossref]  [PubMed]  [PMC]
  40. Nicoloro-SantaBarbara J, Carroll J, Lobel M. Coping, social support, and anxiety in people with mast cell disorders. Ann Allergy Asthma Immunol. 2021;127(4):435-40. [Crossref]  [PubMed]  [PMC]
  41. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215-25. [Crossref]  [PubMed]  [PMC]
  42. Jennings SV, Slee VM, Hobart JS, Thuler LM, Mayne DW, Martín-Martínez M, et al. International Support and Advocacy for Mast Cell Disease Patients and Caregivers. In: Akin, C, eds. The Mastocytosis, A Compherensive Guidebook. Springer Nature Switzerland AG; 2020. pp 267-86. [Crossref]
  43. Sistemik Mastositoz Veri Tabanı Sistemi. Türk Hematoloji Derneği ©2025 [Erişim tarihi: 31 Ocak 2025]. [Link]
  44. Türkiye Ulusal Alerji ve Klinik İmmünoloji Derneği ©2025 [Link]
  45. Mastositozun tedavisi var mı? Türkiye Ulusal Alerji ve Klinik İmmünoloji Derneği ©2021. [Link]
  46. Türkiye Çocuk Alerji İmmünoloji ve Astım Derneği© 2025 [Link]